E-mail a Colleague

Site Map

U.S. Residents Only

Prescribing Info.

Patient Web Site

It looks like you do not have an updated Flash Plug-in. To view the current page, please download it.

OA Severity

> Home > HYALGAN® Facts > Efficacy Data > OA Severity

For osteoarthritis knee pain

Get a jump on OA knee pain

Greater knee pain relief experienced by more patients with Kellgren grade 2 vs grade 4²⁴
Kellgren grade 2 vs grade 4 bar graph

Adapted from Neustadt DH.

Study design

Open trial conducted with 76 patients (92 knees) over the course of 24 months. Intra-articular HYALGAN® 20 mg was administered weekly X 5.

*Kellgren grades 2 through 4 defined as patients with moderate to severe osteoarthritis.

^† >50% reduction in VAS score for pain at rest, night pain, and pain on walking for >1 year.²⁴

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle